Merck Bolsters Januvia Access With Outcomes-Based Discounts To CIGNA
Merck will provide CIGNA with price discounts on Januvia and Janumet that are tied to member outcomes - lower blood sugar and medication adherence - in a novel contract arrangement announced by CIGNA April 23
You may also be interested in...
A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data.
The contracting dispute between the drug chain and PBM may also presage tougher negotiations ahead for biopharmaceutical companies, particularly if Express Scripts is successful in its bid to acquire rival PBM Medco.
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia